# Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

> **NCT04610476** · PHASE3 · UNKNOWN · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 270 (estimated)

## Conditions studied

- Psoriatic Arthritis
- Withdrawal
- Reduction

## Interventions

- **DRUG:** Prednisolone
- **DRUG:** Sulfasalazine
- **DRUG:** Leflunomide
- **DRUG:** Methotrexate
- **DRUG:** Tofacitinib
- **DRUG:** Apremilast
- **DRUG:** Etanercept
- **DRUG:** Adalimumab
- **DRUG:** Infliximab
- **DRUG:** Certolizumab pegol
- **DRUG:** Golimumab
- **DRUG:** Abatacept
- **DRUG:** Secukinumab
- **DRUG:** Ixekizumab
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT04610476
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-19
- **Primary completion:** 2024-10-19
- **Final completion:** 2025-10-19
- **Target enrollment:** 270 (ESTIMATED)
- **Last updated:** 2022-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04610476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04610476, "Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04610476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*